Proposal of modified gastric cancer RECIST (mgcRECIST): CT-based criteria for response assessment in metastatic gastric cancer

Authors: Bagnacci, Giulio; Mura, Gianni; Sica, Cristian; Cartocci, Alessandra; Monteleone, Ilaria; Perrella, Armando; Di Meglio, Nunzia; Lenti, Riccardo; Piccioni, Stefania Angela; Marrelli, Daniele; Bloise, Francesco; Milandri, Carlo; Monti, Manlio; Morgani, Paolo; Prochowski Iamurri, Andrea; Massari, Gaetano; Ministrini, Silvia; Tiberio, Guido Alberto Massimo; Pittiani, Frida; Frittoli, Barbara; Bencivenga, Maria; Filippini, Federica; Ambrosetti, Maria Chiara; Fumagalli Romario, Uberto; Funicelli, Luigi; Reddavid, Rossella; Veltri, Andrea; Bini, Michele; Roviello, Franco; Mazzei, Maria Antonietta

Source journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026-11-20)

DOI: 10.1007/s10120-026-01819-7

Abstract

BACKGROUND: In Western countries, many patients with gastric cancer (GC) are diagnosed at a metastatic stage, with a median overall survival (OS) of less than 12 months. Although imaging is pivotal for staging, restaging, and response assessment, RECIST 1.1 has significant limitations in metastatic GC, particularly for lymph node (LN) and peritoneal involvement. We aimed to propose modified gastric cancer RECIST (mgcRECIST) criteria that better account for these patterns of disease spread. METHODS: In the Italian multicenter prospective METAGASTRO registry, we identified 187 patients with metastatic GC who received at least one chemotherapy cycle and underwent both staging and restaging contrast-enhanced CT. RECIST 1.1 was assessed using three approaches to the primary tumor: D-max, defined as the maximum curvilinear diameter on multiplanar CT images, wall thickness, or exclusion. mgcRECIST integrated RECIST 1.1 using D-max with rPCI progression and persistent lymph nodes with short-axis diameter >/= 15 mm. Overall survival (OS) stratification according to RECIST 1.1 and mgcRECIST was compared. RESULTS: RECIST 1.1 provided the clearest prognostic separation when the primary tumor was included using D-max (p /= 15 mm and rPCI progression >/= 6 points were associated with shorter OS. mgcRECIST yielded distinct prognostic categories, further subdivided RECIST 1.1 response groups, and improved OS concordance compared with RECIST 1.1 using D-max (C-index 0.737 vs. 0.719; p = 0.039). CONCLUSIONS: The proposed mgcRECIST showed promising prognostic stratification and improved prognostic discrimination. If prospectively validated, it may provide a simple, CT-based tool for response assessment and risk stratification in metastatic GC.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.